Picture of ARCA biopharma logo

ABIO ARCA biopharma Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareBalancedMicro CapNeutral

Momentum

Relative Strength (%)
1m+5.75%
3m-5.58%
6m-27.03%
1yr-33.85%
Volume Change (%)
10d/3m+31.28%
Price vs... (%)
52w High-18.06%
50d MA+7.23%
200d MA-5.79%

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital-19.6%
Return on Equity-13.57%
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202431st Dec 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of ARCA biopharma EPS forecast chart

Profile Summary

ARCA biopharma, Inc. is a clinical-stage biopharmaceutical company engaged in developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development. The Company's lead product candidate is Gencaro (bucindolol hydrochloride) for the treatment of atrial fibrillation (AF) in patients with chronic heart failure (HF). Gencaro is being developed for patients who have a genotype that identifies a drug target associated with heightened efficacy. Gencaro is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties that is developing for the treatment of atrial fibrillation in patients with heart failure. Its Recombinant Nematode Anticoagulant Protein c2 (rNAPc2) (AB201), is a protein therapeutic in clinical development as a potential treatment for patients with COVID-19. It is also evaluating options for development of its assets, including partnering and other strategic options.

Directors

Last Annual
December 31st, 2023
Last Interim
December 31st, 2023
Incorporated
March 16th, 2004
Public Since
July 21st, 2000
No. of Shareholders
13
No. of Employees
4
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Capital Market
Shares in Issue
14,501,143

ABIO Share Price Performance

Upcoming Events for ABIO

Q1 2024 ARCA Biopharma Inc Earnings Release

Q2 2024 ARCA Biopharma Inc Earnings Release

Similar to ABIO

Picture of 180 Life Sciences logo

180 Life Sciences

us flag iconNASDAQ Capital Market

Picture of Abeona Therapeutics logo

Abeona Therapeutics

us flag iconNASDAQ Capital Market

Picture of ABVC Biopharma logo

ABVC Biopharma

us flag iconNASDAQ Capital Market

Picture of Acesis Holdings logo

Acesis Holdings

us flag iconNASDAQ Capital Market

Picture of Achieve Life Sciences logo

Achieve Life Sciences

us flag iconNASDAQ Capital Market

FAQ